- Home
- TNXP vs ESEA Comparison
TNXP vs ESEA Comparison
Compare TNXP & ESEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- ESEA
- Stock Information
- Founded
- TNXP 2007
- ESEA 2005
- Country
- TNXP United States
- ESEA Greece
- Employees
- TNXP N/A
- ESEA N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- ESEA Marine Transportation
- Sector
- TNXP Health Care
- ESEA Consumer Discretionary
- Exchange
- TNXP Nasdaq
- ESEA Nasdaq
- Market Cap
- TNXP 207.5M
- ESEA 208.2M
- IPO Year
- TNXP N/A
- ESEA 2006
- Fundamental
- Price
- TNXP $39.78
- ESEA $38.33
- Analyst Decision
- TNXP Strong Buy
- ESEA Buy
- Analyst Count
- TNXP 2
- ESEA 1
- Target Price
- TNXP $585.00
- ESEA $53.00
- AVG Volume (30 Days)
- TNXP 1.3M
- ESEA 23.0K
- Earning Date
- TNXP 05-12-2025
- ESEA 06-10-2025
- Dividend Yield
- TNXP N/A
- ESEA 6.77%
- EPS Growth
- TNXP N/A
- ESEA N/A
- EPS
- TNXP N/A
- ESEA 16.20
- Revenue
- TNXP $10,041,000.00
- ESEA $212,897,313.00
- Revenue This Year
- TNXP $12.17
- ESEA $4.83
- Revenue Next Year
- TNXP $789.15
- ESEA $3.27
- P/E Ratio
- TNXP N/A
- ESEA $2.37
- Revenue Growth
- TNXP N/A
- ESEA 12.43
- 52 Week Low
- TNXP $6.76
- ESEA $24.58
- 52 Week High
- TNXP $558.08
- ESEA $41.43
- Technical
- Relative Strength Index (RSI)
- TNXP 74.56
- ESEA 65.13
- Support Level
- TNXP $25.40
- ESEA $37.52
- Resistance Level
- TNXP $37.84
- ESEA $38.69
- Average True Range (ATR)
- TNXP 4.17
- ESEA 1.33
- MACD
- TNXP 1.75
- ESEA -0.15
- Stochastic Oscillator
- TNXP 87.00
- ESEA 70.28
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.